MTNB RSI Chart
Last 7 days
-6.7%
Last 30 days
21.7%
Last 90 days
27.3%
Trailing 12 Months
-28.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 4.3M | 3.2M | 2.2M | 1.1M |
2022 | 0 | 2.3M | 2.7M | 3.2M |
2021 | 483.7K | 934.4K | 1.4M | 1.8M |
2020 | 0 | 0 | 61.4K | 33.0K |
2019 | 0 | 179.6K | 89.8K | 89.8K |
2018 | 164.7K | 209.6K | 164.7K | 119.8K |
2017 | 151.8K | 119.7K | 104.8K | 149.7K |
2015 | 0 | 0 | 0 | 194.5K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 22, 2022 | conrad herbert j | gifted | - | - | 1,358,120 | - |
Jun 22, 2022 | conrad herbert j | gifted | - | - | -1,358,120 | - |
Dec 31, 2021 | wikler matthew | acquired | - | - | 7,859 | - |
Sep 30, 2021 | wikler matthew | acquired | - | - | 6,106 | - |
Sep 03, 2021 | mannino raphael j | acquired | - | - | 462,150 | chief scientific officer |
Aug 04, 2021 | conrad herbert j | gifted | - | - | 494,622 | - |
Aug 04, 2021 | conrad herbert j | gifted | - | - | -494,622 | - |
Jul 07, 2021 | conrad herbert j | gifted | - | - | -1,280,920 | - |
Jul 07, 2021 | conrad herbert j | gifted | - | - | 1,280,920 | - |
Jun 30, 2021 | wikler matthew | acquired | - | - | 10,244 | - |
Which funds bought or sold MTNB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 6.44 | 876,521 | 2,014,520 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 35,000 | 35,000 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -4,485 | - | -% |
Feb 14, 2024 | Bayesian Capital Management, LP | new | - | 4,065 | 4,065 | -% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 4,127 | 4,127 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 2,974 | 2,974 | -% |
Feb 14, 2024 | LPL Financial LLC | reduced | -0.65 | 52,366 | 132,645 | -% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 8,318 | 20,863 | -% |
Feb 14, 2024 | Royal Bank of Canada | reduced | -3.58 | 1,000 | 2,000 | -% |
Unveiling Matinas BioPharma Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Matinas BioPharma Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Matinas BioPharma Holdings Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Revenue | - | - | - | - | 1,096 | 1,063 | 1,063 | 1,063 | 532 | - | - | 33.00 | 65.00 | 96.00 | 64.00 | 32.00 | - | 90.00 | - | - | 90.00 | 30.00 |
Costs and Expenses | -4.0% | 5,887 | 6,134 | 6,159 | 6,682 | 6,543 | 6,525 | 6,988 | 6,714 | 6,878 | 4,790 | 6,386 | 6,551 | 5,700 | 5,736 | - | 4,561 | 4,610 | 4,167 | 2,954 | 3,495 | 4,151 |
S&GA Expenses | -21.7% | 2,222 | 2,839 | 2,600 | 2,712 | 2,677 | 2,818 | 2,861 | 2,474 | 2,257 | 2,309 | 3,145 | 3,026 | 2,364 | 2,316 | - | 1,890 | 1,782 | 2,474 | 1,575 | 1,972 | 1,958 |
R&D Expenses | 11.2% | 3,665 | 3,295 | 3,559 | 3,970 | 3,867 | 3,707 | 4,127 | 4,240 | 4,621 | 2,481 | 3,241 | 3,526 | 3,336 | 3,420 | - | 2,671 | 2,829 | 1,692 | 1,380 | 1,523 | - |
Net Income | 12.2% | -5,314 | -6,055 | -6,060 | -5,513 | -3,634 | -5,462 | -5,923 | -6,699 | -6,836 | -4,791 | -4,956 | -6,340 | -5,449 | -5,572 | - | -4,404 | -3,344 | -3,626 | -2,935 | -3,411 | -4,110 |
Net Income Margin | -112.6% | -20.93* | -9.85* | -6.41* | -4.79* | -6.59* | -8.79* | -11.12* | -12.68* | -16.55* | -23.05* | -46.22* | -680.21* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -3.2% | -4,579 | -4,435 | -2,235 | -4,129 | -4,341 | -5,220 | -5,186 | -3,993 | -5,973 | -864 | -4,650 | -4,307 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -15.7% | 25.00 | 30.00 | 34.00 | 38.00 | 45.00 | 48.00 | 52.00 | 56.00 | 61.00 | 67.00 | 70.00 | 72.00 | 71.00 | 75.00 | 79.00 | 84.00 | 40.00 | 45.00 | 48.00 | 51.00 | 20.00 |
Current Assets | -22.2% | 16.00 | 20.00 | 24.00 | 28.00 | 35.00 | 37.00 | 42.00 | 45.00 | 51.00 | 56.00 | 61.00 | 63.00 | 62.00 | 65.00 | 69.00 | 74.00 | 30.00 | 34.00 | 37.00 | 40.00 | 13.00 |
Cash Equivalents | -25.3% | 5.00 | 6.00 | 10.00 | 6.00 | 7.00 | 11.00 | 10.00 | 19.00 | 21.00 | 25.00 | 30.00 | 23.00 | 12.00 | 7.00 | 15.00 | 10.00 | 22.00 | 33.00 | 37.00 | 39.00 | 12.00 |
Net PPE | -4.8% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -11.8% | 6.00 | 7.00 | 6.00 | 6.00 | 8.00 | 9.00 | 10.00 | 8.00 | 9.00 | 9.00 | 7.00 | 6.00 | 7.00 | 7.00 | 6.00 | 7.00 | 7.00 | 7.00 | 8.00 | 8.00 | 4.00 |
Current Liabilities | -18.8% | 3.00 | 3.00 | 3.00 | 2.00 | 4.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | 4.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Shareholder's Equity | -16.9% | 19.00 | 23.00 | 28.00 | 33.00 | 37.00 | 39.00 | 43.00 | 48.00 | 52.00 | 58.00 | 63.00 | 67.00 | 64.00 | 68.00 | 73.00 | 78.00 | 33.00 | 38.00 | 40.00 | 43.00 | 16.00 |
Retained Earnings | -3.1% | -175 | -170 | -164 | -158 | -152 | -149 | -143 | -137 | -131 | -124 | -118 | -112 | -107 | -101 | -95.72 | -89.42 | -84.38 | -78.80 | -73.81 | -70.00 | -65.94 |
Additional Paid-In Capital | 0.7% | 195 | 194 | 193 | 191 | 190 | 189 | 187 | 186 | 184 | 183 | 181 | 175 | 167 | 165 | 164 | 163 | 113 | 113 | 105 | 103 | 72.00 |
Shares Outstanding | 0% | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 216 | 208 | 205 | 204 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 165 | - | - | - | 160 | - | - | - | 142 | - | - | - | 112 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -3.6% | -4,579 | -4,419 | -2,193 | -4,087 | -4,299 | -4,970 | -5,131 | -4,756 | -3,957 | -5,749 | -864 | -4,651 | -4,307 | -5,226 | -3,168 | -4,664 | -4,898 | -4,073 | -2,096 | -3,023 | -2,619 |
Share Based Compensation | 6.4% | 1,272 | 1,196 | 1,208 | 1,272 | 1,340 | 1,413 | 1,215 | 1,260 | 1,074 | 1,061 | 1,056 | 1,101 | 1,220 | 953 | 945 | 1,447 | 688 | 671 | 822 | 804 | 1,030 |
Cashflow From Investing | 173.1% | 2,960 | 1,084 | 6,198 | 3,000 | -42.00 | 5,750 | -3,792 | 2,961 | 57.00 | 243 | 7,654 | 8,817 | 9,089 | -2,780 | 7,991 | -54,967 | -5,605 | -73.43 | -317 | -14.25 | - |
Cashflow From Financing | 0% | -1.00 | -1.00 | -1.00 | -4.00 | -5.00 | -3.00 | -6.00 | 93.00 | 8.00 | -8.32 | 180 | 6,785 | 550 | 54.00 | 4.00 | 47,439 | 10.00 | -19.53 | -167 | 30,028 | 8,359 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenue: | ||||
Contract Revenue | $ 1,063 | $ 1,096 | $ 2,125 | |
Costs and expenses: | ||||
Research and development | 3,295 | 3,707 | 10,824 | 12,811 |
General and administrative | 2,839 | 2,818 | 8,151 | 8,424 |
Total costs and expenses | 6,134 | 6,525 | 18,975 | 21,235 |
Loss from operations | (6,134) | (5,462) | (17,879) | (19,110) |
Sale of New Jersey net operating losses & tax credits | 1,734 | |||
Other income, net | 79 | 251 | 13 | |
Net loss | $ (6,055) | $ (5,462) | $ (17,628) | $ (17,363) |
Net loss per share - basic | $ (0.03) | $ (0.03) | $ (0.08) | $ (0.08) |
Net loss per share - diluted | $ (0.03) | $ (0.03) | $ (0.08) | $ (0.08) |
Weighted average common shares outstanding: | ||||
Weighted average common shares outstanding - basic | 217,264,526 | 216,864,526 | 217,264,526 | 216,792,083 |
Weighted average common shares outstanding - diluted | 217,264,526 | 216,864,526 | 217,264,526 | 216,792,083 |
Other comprehensive gain/(loss), net of tax | ||||
Unrealized gain/(loss) on securities available-for-sale | $ 155 | $ (181) | $ 465 | $ (790) |
Other comprehensive gain/(loss), net of tax | 155 | (181) | 465 | (790) |
Comprehensive loss | $ (5,900) | $ (5,643) | $ (17,163) | $ (18,153) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,407 | $ 6,830 |
Marketable debt securities | 11,809 | 21,933 |
Restricted cash – security deposit | 50 | 50 |
Prepaid expenses and other current assets | 1,723 | 5,719 |
Total current assets | 19,989 | 34,532 |
Non-current assets: | ||
Leasehold improvements and equipment – net | 2,021 | 2,091 |
Operating lease right-of-use assets – net | 3,206 | 3,613 |
Finance lease right-of-use assets – net | 22 | 30 |
In-process research and development | 3,017 | 3,017 |
Goodwill | 1,336 | 1,336 |
Restricted cash – security deposit | 200 | 200 |
Total non-current assets | 9,802 | 10,287 |
Total assets | 29,791 | 44,819 |
Current liabilities: | ||
Accounts payable | 835 | 618 |
Accrued expenses | 1,757 | 3,099 |
Operating lease liabilities – current | 632 | 562 |
Financing lease liabilities – current | 5 | 7 |
Total current liabilities | 3,229 | 4,286 |
Non-current liabilities: | ||
Deferred tax liability | 341 | 341 |
Operating lease liabilities – net of current portion | 3,052 | 3,533 |
Financing lease liabilities – net of current portion | 19 | 22 |
Total non-current liabilities | 3,412 | 3,896 |
Total liabilities | 6,641 | 8,182 |
Stockholders’ equity: | ||
Common stock par value $0.0001 per share, 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 217,264,526 issued and outstanding as of September 30, 2023 and December 31, 2022 | 22 | 22 |
Additional paid-in capital | 193,746 | 190,070 |
Accumulated deficit | (170,259) | (152,631) |
Accumulated other comprehensive loss | (359) | (824) |
Total stockholders’ equity | 23,150 | 36,637 |
Total liabilities and stockholders’ equity | $ 29,791 | $ 44,819 |